Neurocognitive functioning in adult WHO grade II gliomas: Impact of old and new treatment modalities

Neuro-Oncology

Volumn 14, Issue SUPPL.4, 2012, Pages

  Klein, Martin ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

chemotherapy, cognition; low grade gliomas; radiotherapy; surgery

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBAMAZEPINE; CARBOPLATIN; CORTICOSTEROID; ETIRACETAM; LOMUSTINE; OXCARBAZEPINE; PHENYTOIN; PROCARBAZINE; TEMOZOLOMIDE; VALPROIC ACID; VINCRISTINE;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT DISEASE; ANTICONVULSANT THERAPY; ARTICLE; ASTROCYTOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; COGNITION; COGNITIVE DEFECT; CORTICOSTEROID THERAPY; CRANIOTOMY; DRUG EFFICACY; DRUG SAFETY; GLIOBLASTOMA; GLIOMA; HUMAN; MOOD DISORDER; MULTIMODALITY CANCER THERAPY; NEUROLOGIC EXAMINATION; NEUROSURGERY; NEUROTOXICITY; OLIGODENDROGLIOMA; PSYCHOSIS; QUALITY OF LIFE; SEIZURE;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; COGNITION DISORDERS; GLIOMA; HUMANS; NEOPLASM GRADING; NEUROSURGICAL PROCEDURES; RADIOTHERAPY; WORLD HEALTH ORGANIZATION;

EID: 84868024273     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos161     Document Type: Article

References (112)

1. McLendon RE, Enterline DS, Tien RD, et al. Tumors of central neuroe-pithelial origin. In: Bigner, DD, McLendon, RE, Bruner, JM eds. Russell and Rubinstein's Pathology of Tumors of the Nervous System. New York: Oxford University Press; 1998:307-572.
2. Kleihues P, Davis RL, Ohgaki H, et al. Diffuse astrocytoma. In: Kleihues, P, Cavenee, WK eds. Pathology and genetics of tumours of the nervous system. Lyon: IARC Press; 2000:22-26.
3. Davis FG, Freels S, Grutsch J, et al. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor his-tological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg. 1998;88:1-10.
4. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004;64:6892-6899. (Pubitemid 39330996)
5. Shafqat S, Hedley-Whyte ET, Henson JW. Age-dependent rate of ana-plastic transformation in low-grade astrocytoma. Neurology. 1999;52:867-869. (Pubitemid 29120202)
6. Cairncross JG, Laperriere NJ. Low-grade glioma. To treat or not to treat?. Arch Neurol. 1989;46:1238-1239. (Pubitemid 19268396)
7. Han SJ, Sughrue ME. The rise and fall of "biopsy and radiate": a history of surgical nihilism in glioma treatment. Neurosurg Clin N Am. 2012;23:207-214 vii.
8. Leighton C, Fisher B, Bauman G, et al. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol. 1997;15:1294-1301. (Pubitemid 27167360)
9. Olson JD, Riedel E, DeAngelis LM. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology. 2000;54:1442-1448. (Pubitemid 30210463)
10. Bosma I, Vos MJ, Heimans JJ, et al. The course of neurocognitive functioning in high-grade glioma patients. Neuro-oncol. 2007;9:53-62. (Pubitemid 46543489)
11. Taphoorn MJB, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol. 2004;3:159-168. (Pubitemid 38229950)
12. Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven low-grade gliomas. Neurology. 2001;56:618-623. (Pubitemid 32209995)
13. Mitchell AJ, Kemp S, Benito-Leon J, Reuber M. The influence of cognitive impairment on health-related quality of life in neurological disease. Acta Neuropsychiatr. 2010;22:2-13.
14. Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002;20:2076-2084. (Pubitemid 34408798)
15. Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low-versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol. 2002;20:2267-2276. (Pubitemid 34441653)
16. Keles GE, Lamborn KR, Berger MS. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg. 2001;95:735-745. (Pubitemid 33043344)
17. Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008;26:1338-1345.
18. McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery. 2008;63:700-707. author reply 707-708.
19. De Witt Hamer PC, Robles SG, Zwinderman AH, Duffau H, Berger MS. Impact of intraoperative stimulation brain mapping on glioma surgery outcome: A meta-analysis. J Clin Oncol. 2012;30:2559-2565.
20. van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade as-trocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery. J Neurol Neurosurg Psychiatry. 1998;64:581-587. (Pubitemid 28204142)
21. Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Ann Neurol. 1992;31:431-436.
22. Ruge MI, Ilmberger J, Tonn JC, Kreth FW. Health-related quality of life and cognitive functioning in adult patients with supratentorial WHO grade II glioma: status prior to therapy. J Neurooncol. 2011;103:129-136.
23. Teixidor P, Gatignol P, Leroy M, et al. Assessment of verbal working memory before and after surgery for low-grade glioma. J Neurooncol. 2007;81:305-313. (Pubitemid 46165335)
24. Braun V, Albrecht A, Kretschmer T, et al. Brain tumour surgery in the vicinity of short-term memory representation-results of neuronavigation using fMRI images. Acta Neurochir (Wien). 2006;148:733-739. (Pubitemid 43974601)
25. Giovagnoli AR, Casazza M, Ciceri E, et al. Preserved memory in temporal lobe epilepsy patients after surgery for low-grade tumour. A pilot study. Neurol Sci. 2007;28:251-258. (Pubitemid 350055434)
26. Friedman MA, Meyers CA, Sawaya R. Neuropsychological effects of third ventricle tumor surgery. Neurosurgery. 2003;52:791-798. (Pubitemid 36402866)
27. Petrucci RJ, Buchheit WA, Woodruff GC, et al. Transcallosal paraforni-cial approach for third ventricle tumors: neuropsychological consequences. Neurosurgery. 1987;20:457-464. (Pubitemid 17040481)
28. Vilkki J, Levanen S, Servo A. Interference in dual-fluency tasks after anterior and posterior cerebral lesions. Neuropsychologia. 2002;40:340-348. (Pubitemid 33001615)
29. Jagaroo V, Rogers MP, Black PM. Allocentric visuospatial processing in patients with cerebral gliomas: a neurocognitive assessment. J Neurooncol. 2000;49:235-248. (Pubitemid 32106786)
30. Kessels RP, Postma A, Kappelle LJ, de Haan EH. Spatial memory impairment in patients after tumour resection: evidence for a double dissociation. J Neurol Neurosurg Ps. 2000;69:389-391. (Pubitemid 30636245)
31. Owen AM, Morris RG, Sahakian BJ, et al. Double dissociations of memory and executive functions in working memory tasks following frontal lobe excisions, temporal lobe excisions or amygdalo-hippocampectomy in man. Brain. 1996;119(Pt 5):1597-1615. (Pubitemid 26375730)
32. Goldstein B, Armstrong CL, John C, Tallent EM. Attention in adult intra-cranial tumors patients. J Clin Exp Neuropsyc. 2003;25:66-78. (Pubitemid 36461160)
33. Vendrell P, Junque C, Pujol J, et al. The role of prefrontal regions in the Stroop task. Neuropsychologia. 1995;33:341-352.
34. Ackermann H, Daum I, Schugens MM, Grodd W. Impaired procedural learning after damage to the left supplementary motor area (SMA). J Neurol Neurosurg Ps. 1996;60:94-97. (Pubitemid 26012275)
35. Scarone P, Gatignol P, Guillaume S, et al. Agraphia after awake surgery for brain tumor: new insights into the anatomo-functional network of writing. Surg Neurol. 2009;72:223-241.
36. Swain SA, Polkey CE, Bullock P, Morris RG. Recognition memory and memory for order in script-based stories following frontal lobe excisions. Cortex. 1998;34:25-45. (Pubitemid 28116325)
37. Owen AM, Downes JJ, Sahakian BJ, et al. Planning and spatial working memory following frontal lobe lesions in man. Neuropsychologia. 1990;28:1021-1034. (Pubitemid 20347464)
38. Vilkki J. Cognitive flexibility and mental programming after closed head injuries and anterior or posterior cerebral excisions. Neuropsychologia. 1992;30:807-814.
39. Hornak J, O'Doherty J, Bramham J, et al. Reward-related reversal learning after surgical excisions in orbito-frontal or dorsolateral prefrontal cortex in humans. J Cogn Neurosci. 2004;16:463-478. (Pubitemid 38392404)
40. Miotto EC, Morris RG. Virtual planning in patients with frontal lobe lesions. Cortex. 1998;34:639-657. (Pubitemid 29004881)
41. Goldstein LH, Bernard S, Fenwick PB, et al. Unilateral frontal lobectomy can produce strategy application disorder. J Neurol Neurosurg Ps. 1993;56:274-276. (Pubitemid 23101208)
42. Armstrong CL, Hunter JV, Hackney D, et al. MRI changes due to early-delayed conformal radiotherapy and postsurgical effects in patients with brain tumors. Int J Radiat Oncol Biol Phys. 2005;63:56-63. (Pubitemid 41583542)
43. De Benedictis A, Moritz-Gasser S, Duffau H. Awake mapping optimizes the extent of resection for low-grade gliomas in eloquent areas. Neurosurgery. 2010;66:1074-1084.
44. Sarubbo S, Latini F, Panajia A, et al. Awake surgery in low-grade gliomas harboring eloquent areas:3-year mean follow-up. Neurol Sci. 2011;32:801-810.
45. Duffau H. New concepts in surgery of WHO grade II gliomas: functional brain mapping, connectionism and plasticity-a review. J Neurooncol. 2006;79:77-115. (Pubitemid 44057422)
46. Chang EF, Clark A, Smith JS, et al. Functional mapping-guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long-term survival. Clinical article. J Neurosurg. 2011;114:566-573.
47. Gil-Robles S, Duffau H. Surgical management of World Health Organization Grade II gliomas in eloquent areas: the necessity of preserving a margin around functional structures. Neurosurg Focus. 2010;28:E8.
48. Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the left dominant hemisphere: toward a "supratotal" resection. Clinical article. J Neurosurg. 2011;115:232-239.
49. van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligoden-droglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005;366:985-990. (Pubitemid 41323034)
50. Bé hin A, Delattre JY. Neurologic sequelae of radiotherapy of the nervous system. In: Schiff, D, Wen, PY eds. Cancer Neurology in clinical practice. Totowa: Humana Press; 2003:173-192.
51. Crossen JR, Garwood D, Glatstein E, Neuwelt EA. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol. 1994;12:627-642. (Pubitemid 24079908)
52. Monje ML, Palmer T. Radiation injury and neurogenesis. Curr Opin Neurol. 2003;16:129-134. (Pubitemid 36521196)
53. Constine LS, Milano MT, Friedman D, et al. Late effects of cancer treatment on normal tissues. In: Halperin, EC, Perez, CA, Brady, LW, Wazer, DE, Freeman, C, Prosnitz, LR eds. Perez and Brady's principles and practice of radiation oncology. Philadelphia: Lippincot Williams & Wilkins; 2008:320-355.
54. Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009;8:810-818.
55. Postma TJ, Klein M, Verstappen CC, et al. Radiotherapy-induced cerebral abnormalities in patients with low-grade glioma. Neurology. 2002;59:121-123. (Pubitemid 34742806)
56. Surma-aho O, Niemela M, Vilkki J, et al. Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology. 2001;56:1285-1290. (Pubitemid 32455284)
57. Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet. 2002;360:1361-1368. (Pubitemid 35341299)
58. Klein M, Engelberts NHJ, Van der Ploeg HM, et al. Epilepsy in low-grade gliomas: the impact on cognitive functioning and quality of life. Ann Neurol. 2003;54:514-520. (Pubitemid 37176548)
59. Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J Neurosurg. 1993;78:909-914. (Pubitemid 23159327)
60. Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolo-mide chemotherapy in patients with WHO grade II gliomas. Ann Oncol. 2003;14:1715-1721. (Pubitemid 38029041)
61. Buckner JC, Gesme D, Jr., O'Fallon JR, et al. Phase II trial of procarba-zine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol. 2003;21:251-255. (Pubitemid 46606153)
62. Hoang-Xuan K, Capelle L, Kujas M, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocyto-mas and correlation with chromosome 1p deletions. J Clin Oncol. 2004;22:3133-3138. (Pubitemid 41103727)
63. Kaloshi G, Benouaich-Amiel A, Diakite F, et al. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology. 2007;68:1831-1836. (Pubitemid 46791397)
64. Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. Eur J Neurol. 2007;14:391-398. (Pubitemid 46481159)
65. Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol. 2003;14:1722-1726. (Pubitemid 38029042)
66. Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolo-mide in patients with progressive low-grade glioma. J Clin Oncol. 2003;21:646-651. (Pubitemid 46621898)
67. Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procar-bazine, lomustine, and vincristine. Cancer. 2005;103:802-809. (Pubitemid 40216410)
68. Duffau H, Taillandier L, Capelle L. Radical surgery after chemotherapy: a new therapeutic strategy to envision in grade II glioma. J Neurooncol. 2006;80:171-176. (Pubitemid 44614799)
69. Spena G, Garbossa D, Barletta L, et al. Preoperative chemotherapy for infiltrative low-grade oligoastrocytoma: a useful strategy to maximize surgical resection-case report. Neurol Med Chir (Tokyo). 2010;50:410-413.
70. Blonski M, Taillandier L, Herbet G, et al. Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life. J Neurooncol. 2012;106:353-366.
71. Shapiro WR, Green SB. Reevaluating the efficacy of intra-arterial BCNU. J Neurosurg. 1987;66:313-315.
72. Shapiro WR, Green SB, Burger PC, et al. A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg. 1992;76:772-781.
73. Bellavance MA, Blanchette M, Fortin D. Recent advances in blood-brain barrier disruption as a CNS delivery strategy. AAPS J. 2008;10:166-177.
74. DeAngelis LM, Yahalom J, Thaler HT, et al. Combined modality therapy for primary CNS lymphoma. J Clin Oncol. 1992;10:635-643.
75. Philips PC. Methotrexate toxicity. In: Rottenberg, DA ed. Neurological complications of cancer treatment. Boston: Butterworth-Heinemann; 1991:115-134.
76. Wen PY. Central nervous system complications of cancer therapy. In Schiff, D, Wen, PY eds. Cancer Neurology in Clinical Practice. Totowa: Humana Press; 2003:215-231.
77. Ahles TA, Saykin AJ, Noll WW, et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology. 2003;12:612-619. (Pubitemid 37086736)
78. EORTC Brain Tumor Group: EORTC protocol 22033-26033. Primary chemotherapy with temozolomide vs.radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss : a phase III study. http://www.eortc.be/ protoc/details.asp?protocol=22033. EORTC. Accessed June 8, 2012.
79. Packer RJ, Jakacki R, Horn M, et al. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer. 2009;52:791-795.
80. Couec ML, Andre N, Thebaud E, et al. Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: Toxicity and efficacy trends. Pediatr Blood Cancer. 2012;59:34-38.
81. Wefel JS, Cloughesy T, Zazzali JL, et al. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro-oncol. 2011;13:660-668.
82. Hilverda K, Bosma I, Heimans JJ, et al. Cognitive functioning in glioblas-toma patients during radiotherapy and temozolomide treatment: initial findings. J Neurooncol. 2010;97:89-94.
83. Levin VA, Yung WK, Bruner J, et al. Phase II study of accelerated frac-tionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys. 2002;53:58-66. (Pubitemid 34465808)
84. Lote K, Stenwig AE, Skullerud K, et al. Prevalence and prognostic significance of epilepsy in patients with gliomas. Eur J Cancer. 1998;34:98-102. (Pubitemid 28123388)
85. Haglund MM, Berger MS, Kunkel DD, et al. Changes in gamma-aminobutyric acid and somatostatin in epileptic cortex associated with low-grade gliomas. J Neurosurg. 1992;77:209-216.
86. Berger MS, Ghatan S, Haglund MM, et al. Low-grade gliomas associated with intractable epilepsy: seizure outcome utilizing electrocorticography during tumor resection. J Neurosurg. 1993;79:62-69. (Pubitemid 23182745)
87. Rogers LR, Morris HH, Lupica K. Effect of cranial irradiation on seizure frequency in adults with low-grade astrocytoma and medically intractable epilepsy. Neurology. 1993;43:1599-1601. (Pubitemid 23230553)
88. Englot DJ, Berger MS, Barbaro NM, Chang EF. Predictors of seizure freedom after resection of supratentorial low-grade gliomas. A review. J Neurosurg. 2011;115:240-244.
89. Englot DJ, Han SJ, Berger MS, et al. Extent of surgical resection predicts seizure freedom in low-grade temporal lobe brain tumors. Neurosurgery. 2012;70:921-928. discussion 928.
90. Dodrill CB. Progressive cognitive decline in adolescents and adults with epilepsy. Prog Brain Res. 2002;135:399-407. (Pubitemid 35461036)
91. Correa DD, DeAngelis LM, Shi W, et al. Cognitive functions in low-grade gliomas: disease and treatment effects. J Neurooncol. 2007;81:175-184. (Pubitemid 44963976)
92. Drane LD, Meador KJ. Cognitive and behavioral effects of antiepileptic drugs. Epilepsy Behav. 2002;3:49-53.
93. Meador KJ. Cognitive outcomes and predictive factors in epilepsy. Neurology. 2002;58:21-26.
94. Maschio M, Dinapoli L, Zarabia A, et al. Issues related to the pharmacological management of patients with brain tumours and epilepsy. Funct Neurol. 2006;21:15-19. (Pubitemid 43985840)
95. Oberndorfer S, Piribauer M, Marosi C, et al. P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol. 2005;72:255-260. (Pubitemid 40867409)
96. Struik K, Klein M, Heimans JJ, et al. Fatigue in low-grade glioma. J Neurooncol. 2009;92:73-78.
97. Maschio M, Dinapoli L, Vidiri A, et al. The role side effects play in the choice of antiepileptic therapy in brain tumor-related epilepsy: a comparative study on traditional antiepileptic drugs versus oxcarbazepine. J Exp Clin Cancer Res. 2009;28:60.
98. Dinapoli L, Maschio M, Jandolo B, et al. Quality of life and seizure control in patients with brain tumor-related epilepsy treated with leve-tiracetam monotherapy: preliminary data of an open-label study. [published online ahead of print May 5, 2009]. Neurol Sci. 2009. doi:10.1007/s10072-009- 0087-x.
99. Meador KJ. Cognitive and memory effects of the new antiepileptic drugs. Epilepsy Res. 2006;68:63-67. (Pubitemid 43052784)
100. Meador KJ, Gevins A, Loring DW, et al. Neuropsychological and neuro-physiologic effects of carbamazepine and levetiracetam. Neurology. 2007;69:2076-2084. (Pubitemid 350175710)
101. Lim DA, Tarapore P, Chang E, et al. Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. J Neurooncol. 2009;93:349-354.
102. Fietta P, Fietta P, Delsante G. Central nervous system effects of natural and synthetic glucocorticoids. Psychiatry Clin Neurosci. 2009;63:613-622.
103. Wolkowitz OM, Lupien SJ, Bigler E, et al. The "steroid dementia syndrome": an unrecognized complication of glucocorticoid treatment. Ann N Y Acad Sci. 2004;1032:191-194. (Pubitemid 40298473)
104. Brown ES. Effects of glucocorticoids on mood, memory, and the hippocampus. Treatment and preventive therapy. Ann N Y Acad Sci. 2009;1179:41-55.
105. Brown PD, Ballman KV, Rummans TA, et al. Prospective study of quality of life in adults with newly diagnosed high-grade gliomas. J Neurooncol. 2006;76:283-291.
106. Brown PD, Buckner JC, O'Fallon JR, et al. Importance of baseline minimental state examination as a prognostic factor for patients with low-grade glioma. Int J Radiat Oncol Biol Phys. 2004;59:117-125. (Pubitemid 38501515)
107. Armstrong CL, Goldstein B, Shera D, et al. The predictive value of longitudinal neuropsychologic assessment in the early detection of brain tumor recurrence. Cancer. 2003;97:649-656. (Pubitemid 36125842)
108. Meyers CA, Hess KR, Yung WK, et al. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol. 2000;18:646-650. (Pubitemid 30078546)
109. Meyers CA, Hess KR. Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro-oncol. 2003;5:89-95. (Pubitemid 36416837)
110. Benedict RHB, Schretlen D, Groninger L, et al. Hopkins Verbal Learning Test-Revised: Normative data and analysis of inter-form and test-retest reliability. Clinical Neuropsychology. 1998;12:43-55. (Pubitemid 28168220)
111. Benton AL, Hamsher K. Multilingual Aphasia Examination. Iowa City, Iowa, USA: AJA Associates, 1989.
112. Lezak MD, Howieson DB, Loring DW. Neuropsychological Assessment. New York: Oxford University Press, 2004.